Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT01874431




Registration number
NCT01874431
Ethics application status
Date submitted
7/06/2013
Date registered
11/06/2013
Date last updated
1/07/2021

Titles & IDs
Public title
Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
Scientific title
A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Assess the Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
Secondary ID [1] 0 0
2012-004179-38
Secondary ID [2] 0 0
16243
Universal Trial Number (UTN)
Trial acronym
ARTS-DN
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Diabetic Nephropathies 0 0
Condition category
Condition code
Renal and Urogenital 0 0 0 0
Kidney disease
Metabolic and Endocrine 0 0 0 0
Diabetes

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Experimental: Finerenone (BAY94-8862) (1.25 mg) - 1.25 mg dose oral once daily for 90 days

Experimental: Finerenone (BAY94-8862)(2.5 mg) - 2.5 mg dose oral once daily for 90 days

Experimental: Finerenone (BAY94-8862)(5 mg) - 5 mg dose oral once daily for 90 days

Experimental: Finerenone (BAY94-8862)(7.5 mg) - 7.5 mg dose oral once daily for 90 days

Experimental: Finerenone (BAY94-8862) (10 mg) - 10 mg dose oral once daily for 90 days

Experimental: Finerenone (BAY94-8862) (15 mg) - 15 mg dose oral once daily for 90 days

Experimental: Finerenone (BAY94-8862)(20 mg) - 20 mg dose oral once daily for 90 days

Placebo comparator: Placebo - Placebo oral dose once daily for 90 days
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Ratio of UACR at Day 90 to UACR at Baseline
Timepoint [1] 0 0
Baseline and Day 90±2
Secondary outcome [1] 0 0
Change From Baseline to Day 90 in Serum Potassium
Timepoint [1] 0 0
Baseline and Day 90±2
Secondary outcome [2] 0 0
Change From Baseline to Day 90 in eGFR
Timepoint [2] 0 0
Baseline and Day 90±2
Secondary outcome [3] 0 0
Change From Baseline to Day 90 in KDQOL-36 Domain Score (Effects of Kidney Disease)
Timepoint [3] 0 0
Baseline and Day 90±2
Secondary outcome [4] 0 0
Change From Baseline to Day 90 in EQ-5D Scores (EQ5D - Visual Analog Scale)
Timepoint [4] 0 0
Baseline and Day 90±2

Eligibility
Key inclusion criteria
* Men and women aged 18 years and older.The lower age limit may be higher if legally required in the participating country
* Women of childbearing potential can only be included in the study if a pregnancy test is negative and if they agree to use adequate contraception when sexually active.
* Subjects with type 2 diabetes mellitus fulfilling at least 1 of the following criteria

* are on oral antidiabetics and / or insulin,
* have a documented fasting glucose >/= 7.0 mmol/L in the medical history,
* have a 2 hour plasma glucose >/=11.1 mmol/L during an oral glucose tolerance test in the medical history, or
* have a glycated hemoglobin (HbA1c) >/=6.5% [National Glycohemoglobin Standardization Program (NGSP) / Diabetes Control and Complications Trial (DCCT)] in the medical history or at the run-in visit
* Subjects with a clinical diagnosis of diabetic nephropathy (DN) based on at least 1 of the following criteria:

* Persistent very high albuminuria defined as urinary albumin-to-creatine ratio (UACR) of >/=300 mg/g ( >/= 34 mg/mmol) in 2 out of 3 first morning void samples and estimated glomerular filtration rate (eGFR) >/=30 mL/min/1.73 m² but < 90 mL/min/1.73m² (Chronic Kidney Disease Epidemiology Collaboration, CKD EPI) (mL = milliliter; min = minute; m2 = square meter; g = gram; mmol = millimole) or
* Persistent high albuminuria defined as UACR of >/=30 mg/g but <300 mg/g in (>/=3.4mg/mmol but <34 mg/mmol) in 2 out of 3 first morning void samples and eGFR >/=30 mL/min/1.73 m² but < 90 mL/min/1.73m²
* Subjects treated with an angiotensin-converting enzyme inhibitor (ACEI) and/or angiotensin receptor blocker (ARB) for at least 3 months without any adjustments to this therapy for at least 4 weeks prior to the screening visit
* Serum potassium </= 4.8 mmol/L at both the run-in visit and the screening visit
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Non-diabetic renal disease
* Glycated hemoglobin (HbA1c) >12% at the run-in visit or the screening visit
* UACR >3000 mg/g (339mg/mmol) in any of the urinary first morning void samples at the run-in visit or screening visit
* Hypertension with mean sitting systolic blood pressure (SBP) >/=180 mmHg or mean sitting diastolic blood pressure (DBP) >/=110 mmHg at the run-in visit or mean supine SBP >/=160 mmHg or mean sitting DBP >/=100 mmHg at the screening visit
* Subjects with a clinical diagnosis of heart failure with reduced ejection fraction (HFrEF) and persistent symptoms (New York Heart Association class II-IV) at the run-in visit
* Concomitant therapy with eplerenone, spironolactone, any renin inhibitor, or potassium-sparing diuretic
* Dialysis for acute renal failure within the previous 6 months prior to the run-in visit

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
12/06/2013
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
7/08/2014
Sample size
Target
Accrual to date
Final
823
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Recruitment hospital [1] 0 0
- St Leonards
Recruitment hospital [2] 0 0
- Clayton
Recruitment hospital [3] 0 0
- Melbourne
Recruitment hospital [4] 0 0
- Prahran
Recruitment hospital [5] 0 0
- Reservoir
Recruitment hospital [6] 0 0
- Box Hill
Recruitment hospital [7] 0 0
- Woolloongabba
Recruitment postcode(s) [1] 0 0
2065 - St Leonards
Recruitment postcode(s) [2] 0 0
3168 - Clayton
Recruitment postcode(s) [3] 0 0
3052 - Melbourne
Recruitment postcode(s) [4] 0 0
3181 - Prahran
Recruitment postcode(s) [5] 0 0
3073 - Reservoir
Recruitment postcode(s) [6] 0 0
3128 - Box Hill
Recruitment postcode(s) [7] 0 0
4102 - Woolloongabba
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Connecticut
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Illinois
Country [6] 0 0
United States of America
State/province [6] 0 0
Michigan
Country [7] 0 0
United States of America
State/province [7] 0 0
New York
Country [8] 0 0
United States of America
State/province [8] 0 0
South Carolina
Country [9] 0 0
United States of America
State/province [9] 0 0
Tennessee
Country [10] 0 0
United States of America
State/province [10] 0 0
Texas
Country [11] 0 0
United States of America
State/province [11] 0 0
Vermont
Country [12] 0 0
Austria
State/province [12] 0 0
Graz
Country [13] 0 0
Austria
State/province [13] 0 0
Innsbruck
Country [14] 0 0
Austria
State/province [14] 0 0
Salzburg
Country [15] 0 0
Austria
State/province [15] 0 0
St. Pölten
Country [16] 0 0
Austria
State/province [16] 0 0
Wien
Country [17] 0 0
Bulgaria
State/province [17] 0 0
Haskovo
Country [18] 0 0
Bulgaria
State/province [18] 0 0
Lukovit
Country [19] 0 0
Bulgaria
State/province [19] 0 0
Plovdiv
Country [20] 0 0
Bulgaria
State/province [20] 0 0
Ruse
Country [21] 0 0
Bulgaria
State/province [21] 0 0
Sofia
Country [22] 0 0
Bulgaria
State/province [22] 0 0
Stara Zagora
Country [23] 0 0
Bulgaria
State/province [23] 0 0
Varna
Country [24] 0 0
Canada
State/province [24] 0 0
British Columbia
Country [25] 0 0
Canada
State/province [25] 0 0
Ontario
Country [26] 0 0
Canada
State/province [26] 0 0
Quebec
Country [27] 0 0
Czechia
State/province [27] 0 0
Chrudim
Country [28] 0 0
Czechia
State/province [28] 0 0
Koprivnice
Country [29] 0 0
Czechia
State/province [29] 0 0
Krnov
Country [30] 0 0
Czechia
State/province [30] 0 0
Praha 2
Country [31] 0 0
Denmark
State/province [31] 0 0
Aarhus C
Country [32] 0 0
Denmark
State/province [32] 0 0
Gentofte
Country [33] 0 0
Denmark
State/province [33] 0 0
Herlev
Country [34] 0 0
Denmark
State/province [34] 0 0
Hillerød
Country [35] 0 0
Denmark
State/province [35] 0 0
Holbaek
Country [36] 0 0
Denmark
State/province [36] 0 0
Holstebro
Country [37] 0 0
Denmark
State/province [37] 0 0
Kolding
Country [38] 0 0
Finland
State/province [38] 0 0
Helsinki
Country [39] 0 0
Finland
State/province [39] 0 0
Jyväskylä
Country [40] 0 0
Finland
State/province [40] 0 0
Oulu
Country [41] 0 0
Finland
State/province [41] 0 0
Tampere
Country [42] 0 0
Finland
State/province [42] 0 0
Turku
Country [43] 0 0
France
State/province [43] 0 0
Amiens
Country [44] 0 0
France
State/province [44] 0 0
La Tronche
Country [45] 0 0
France
State/province [45] 0 0
Lyon Cedex
Country [46] 0 0
France
State/province [46] 0 0
Paris Cedex 15
Country [47] 0 0
France
State/province [47] 0 0
Strasbourg
Country [48] 0 0
Germany
State/province [48] 0 0
Niedersachsen
Country [49] 0 0
Germany
State/province [49] 0 0
Nordrhein-Westfalen
Country [50] 0 0
Germany
State/province [50] 0 0
Rheinland-Pfalz
Country [51] 0 0
Hong Kong
State/province [51] 0 0
Hong Kong
Country [52] 0 0
Hong Kong
State/province [52] 0 0
Shatin
Country [53] 0 0
Hungary
State/province [53] 0 0
Budapest
Country [54] 0 0
Hungary
State/province [54] 0 0
Debrecen
Country [55] 0 0
Hungary
State/province [55] 0 0
Eger
Country [56] 0 0
Hungary
State/province [56] 0 0
Nagykanizsa
Country [57] 0 0
Hungary
State/province [57] 0 0
Papa
Country [58] 0 0
Israel
State/province [58] 0 0
Ashkelon
Country [59] 0 0
Israel
State/province [59] 0 0
Holon
Country [60] 0 0
Israel
State/province [60] 0 0
Jerusalem
Country [61] 0 0
Israel
State/province [61] 0 0
Kfar Saba
Country [62] 0 0
Israel
State/province [62] 0 0
Petach Tikva
Country [63] 0 0
Israel
State/province [63] 0 0
Tel Aviv
Country [64] 0 0
Italy
State/province [64] 0 0
Campania
Country [65] 0 0
Italy
State/province [65] 0 0
Lombardia
Country [66] 0 0
Italy
State/province [66] 0 0
Puglia
Country [67] 0 0
Italy
State/province [67] 0 0
Sardegna
Country [68] 0 0
Italy
State/province [68] 0 0
Toscana
Country [69] 0 0
Italy
State/province [69] 0 0
Veneto
Country [70] 0 0
Korea, Republic of
State/province [70] 0 0
Busan
Country [71] 0 0
Korea, Republic of
State/province [71] 0 0
Seoul
Country [72] 0 0
Netherlands
State/province [72] 0 0
AlMERE
Country [73] 0 0
Netherlands
State/province [73] 0 0
Eindhoven
Country [74] 0 0
Netherlands
State/province [74] 0 0
Groningen
Country [75] 0 0
Netherlands
State/province [75] 0 0
Hoogeveen
Country [76] 0 0
Netherlands
State/province [76] 0 0
Maastricht
Country [77] 0 0
Norway
State/province [77] 0 0
Hamar
Country [78] 0 0
Norway
State/province [78] 0 0
Ålesund
Country [79] 0 0
Poland
State/province [79] 0 0
Bialystok
Country [80] 0 0
Poland
State/province [80] 0 0
Bydgoszcz
Country [81] 0 0
Poland
State/province [81] 0 0
Lodz
Country [82] 0 0
Poland
State/province [82] 0 0
Lublin
Country [83] 0 0
Poland
State/province [83] 0 0
Olawa
Country [84] 0 0
Poland
State/province [84] 0 0
Warszawa
Country [85] 0 0
Poland
State/province [85] 0 0
Wroclaw
Country [86] 0 0
Portugal
State/province [86] 0 0
Almada
Country [87] 0 0
Portugal
State/province [87] 0 0
Lisboa
Country [88] 0 0
South Africa
State/province [88] 0 0
Gauteng
Country [89] 0 0
South Africa
State/province [89] 0 0
KwaZulu Natal
Country [90] 0 0
South Africa
State/province [90] 0 0
Kwazulu-Natal
Country [91] 0 0
South Africa
State/province [91] 0 0
Western Cape
Country [92] 0 0
Spain
State/province [92] 0 0
A Coruña
Country [93] 0 0
Spain
State/province [93] 0 0
Cádiz
Country [94] 0 0
Spain
State/province [94] 0 0
Valencia
Country [95] 0 0
Spain
State/province [95] 0 0
Barcelona
Country [96] 0 0
Spain
State/province [96] 0 0
Girona
Country [97] 0 0
Spain
State/province [97] 0 0
Madrid
Country [98] 0 0
Sweden
State/province [98] 0 0
Karlstad
Country [99] 0 0
Sweden
State/province [99] 0 0
Kristianstad
Country [100] 0 0
Sweden
State/province [100] 0 0
Skövde
Country [101] 0 0
Sweden
State/province [101] 0 0
Stockholm
Country [102] 0 0
Sweden
State/province [102] 0 0
Uppsala
Country [103] 0 0
Sweden
State/province [103] 0 0
Vällingby
Country [104] 0 0
Sweden
State/province [104] 0 0
Örebro
Country [105] 0 0
Taiwan
State/province [105] 0 0
Kaohsiung
Country [106] 0 0
Taiwan
State/province [106] 0 0
Taipei

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Bayer
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
To assess a new drug, BAY94-8862 given orally at different doses, to evaluate whether it was safe and can help the well being of patients with type 2 diabetes and diabetic nephropathy. These treatment doses were compared to placebo.
Trial website
https://clinicaltrials.gov/study/NCT01874431
Trial related presentations / publications
Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, Remuzzi G, Rossing P, Schmieder RE, Nowack C, Kolkhof P, Joseph A, Pieper A, Kimmeskamp-Kirschbaum N, Ruilope LM; Mineralocorticoid Receptor Antagonist Tolerability Study-Diabetic Nephropathy (ARTS-DN) Study Group. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial. JAMA. 2015 Sep 1;314(9):884-94. doi: 10.1001/jama.2015.10081.
Snelder N, Heinig R, Drenth HJ, Joseph A, Kolkhof P, Lippert J, Garmann D, Ploeger B, Eissing T. Population Pharmacokinetic and Exposure-Response Analysis of Finerenone: Insights Based on Phase IIb Data and Simulations to Support Dose Selection for Pivotal Trials in Type 2 Diabetes with Chronic Kidney Disease. Clin Pharmacokinet. 2020 Mar;59(3):359-370. doi: 10.1007/s40262-019-00820-x.
Chung EY, Ruospo M, Natale P, Bolignano D, Navaneethan SD, Palmer SC, Strippoli GF. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev. 2020 Oct 27;10(10):CD007004. doi: 10.1002/14651858.CD007004.pub4.
Erraez S, Lopez-Mesa M, Gomez-Fernandez P. Mineralcorticoid receptor blockers in chronic kidney disease. Nefrologia (Engl Ed). 2021 May-Jun;41(3):258-275. doi: 10.1016/j.nefro.2020.10.001. Epub 2020 Dec 24. English, Spanish.
Public notes

Contacts
Principal investigator
Name 0 0
Bayer Study Director
Address 0 0
Bayer
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT01874431